Euglycemic Diabetic Ketoacidosis in Patients Taking Sodium-Glucose Co-Transporter 2 (SGLT2) Inhibitors: Review of the Literature

This paper provides an overview of euglycemic diabetic ketoacidosis (euDKA) associated with the use of sodium-glucose co-transporter 2 (SGLT2) inhibitors. euDKA is a rare but potentially life-threatening complication that can occur in patients taking SGLT2 inhibitors, and its clinical presentation differs from traditional diabetic ketoacidosis. This paper discusses the epidemiology, pathophysiology, clinical manifestations, diagnosis, and treatment of euDKA. Prompt recognition and appropriate treatment are critical to prevent morbidity and mortality. Healthcare providers should be aware of the potential risk of euDKA in patients taking SGLT2 inhibitors and educate them on the signs and symptoms of this serious complication. Further research is needed to better understand the pathophysiology of euDKA and identify strategies for its prevention and treatment.